Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODEN: OSU6162 add-on in SSRI/SNRI-resistant depression
2020-005860-69Phase 2Active
- Sponsor
- University of Gothenburg
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) and treatment-resistant depression (TRD) comparing OSU6162 add-on with Placebo add-on (2 arms). Primary endpoint: Change from baseline in Bech 6-item HDRS total score at endpoint. Started Mar 2021; status: active.
02
Drugs
OSU-6162
03
Conditions
major depressive disorder (MDD)treatment-resistant depression (TRD)
Beyond the preview
Go deeper on 2020-005860-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005860-69.